title: Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.
abstract: Whereas tumor cells are poor immunogens, recombinant tumor cells or dendritic cells as well as engineered viruses have been demonstrated to elicit specific antitumor immune responses leading to tumor growth suppression and long-lasting immunity in mouse tumor models. Single cytotoxic T lymphocyte-defined epitope-based strategies have proved useful for immunization in tumor-bearing mice. This strategy is under investigation in human melanoma, along with adjuvants such as cytokines or dendritic cells. Flt3L is an in vivo dendritic-cell growth factor that offers new prospects in the field of active specific immunotherapy. These immunotherapeutic approaches are being tested in clinical trials, and may open up novel avenues for disease-free patients with poor prognostic factors.
authors.affiliation: CNRS URA 1301, Institut Gustave Roussy, Villejuif, France.
authors.forename: N
authors.initials: N
authors.lastname: Fernandez
authors.forename: M T
authors.initials: MT
authors.lastname: Duffour
authors.forename: M
authors.initials: M
authors.lastname: Perricaudet
authors.forename: M T
authors.initials: MT
authors.lastname: Lotze
authors.forename: T
authors.initials: T
authors.lastname: Tursz
authors.forename: L
authors.initials: L
authors.lastname: Zitvogel
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000235:genetics / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D010455:Peptides / Q000276:immunology; D011518:Proto-Oncogene Proteins / Q000276:immunology; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology; D040281:Vascular Endothelial Growth Factor Receptor-1
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines; D010455:Peptides; D011518:Proto-Oncogene Proteins; D019444:Vaccines, DNA; D020794:Receptor Protein-Tyrosine Kinases; D040281:Vascular Endothelial Growth Factor Receptor-1